IP Library › Granted Patent US 11,352,444
Granted Patent B2
US 11,352,444 · App. 15/463,752 · Granted Jun 7, 2022

Genetic engineering of non-human animals for the production of chimeric antibodies

Inventors: Larry Green (San Francisco, CA); Hiroaki Shizuya (South Pasadena, CA)
Assignee: ABLEXIS, LLC
C07K16/461A01K67/0275A01K67/0278C07K16/00C07K16/18C12N15/8509A01K2207/15A01K2217/052A01K2217/072A01K2227/105A01K2267/01C07K2317/14C07K2317/24C07K2317/51C07K2317/515C07K2317/52C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/56C07K2317/64C12N2510/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,352,444
App. No.
15/463,752
Granted
Jun 7, 2022
Kind
B2
Abstract

The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.

Claims (11)

1. A chimeric antibody, or antigen-binding fragment thereof, comprising (i) a chimeric immunoglobulin heavy chain comprising a human immunoglobulin heavy chain variable region and a chimeric immunoglobulin heavy chain constant region, wherein the constant region comprises a human CH1 domain, a human upper hinge region, a murine CH2 domain, and a murine CH3 domain and (ii) an immunoglobulin light chain.

2. The chimeric antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the CH1 domain isotype is selected from the group consisting of IgM, IgD, IgG1, IgG2, IgG3, IgG4, IgA, and IgE.

3. The chimeric antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the upper hinge region isotype is selected from the group consisting of IgM, IgD, IgG1, IgG2, IgG3, IgG4, IgA, and IgE.

4. The chimeric antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the immunoglobulin light chain is an immunoglobulin lambda light chain.

5. The chimeric antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the immunoglobulin light chain is an immunoglobulin kappa light chain.

6. The chimeric antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the immunoglobulin light chain is human.

7. The chimeric antibody, or antigen-binding fragment thereof, according to claim 6 , wherein the murine CH2 domain and the murine CH3 domain are mouse.

8. The chimeric antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the immunoglobulin light chain is murine.

9. The chimeric antibody, or antigen-binding fragment thereof, according to claim 8 , wherein the immunoglobulin light chain is mouse.

10. The chimeric antibody, or antigen-binding fragment thereof, according to claim 4 , wherein the murine CH2 domain and the murine CH3 domain are mouse.

11. The chimeric antibody, or antigen-binding fragment thereof, according to claim 5 , wherein the murine CH2 domain and the murine CH3 domain are mouse.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2017
From: GREEN, LARRY; SHIZUYA, HIROAKI
To: ABLEXIS, LLC
Reel/Frame 041647/0441 →
Continuity (5)
Division 15408114 · Jan 17, 2017
Division 13638522
Provisional Application 61361302 · Jul 2, 2010
Provisional Application 61319690 · Mar 31, 2010
Related Publication 20170188557A1 · Jul 6, 2017